Loading
Neurotransmitter Receptor Influence on Behavior / Regulation of Appetite and Obesity · Journal article
Nature Communications · September 3, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic mouse model study demonstrating that clozapine-induced weight gain in female mice involves a novel G-protein-independent coupling between the MC4R and Kir7.1 potassium channel in hypothalamic neurons. Genetic deletion or pharmacological inhibition of Kir7.1 reversed weight gain while preserving antipsychotic efficacy in behavioral assays, identifying a potential therapeutic target. The work is exploratory and preclinical; clinical relevance and human applicability remain to be established.
Experimental animal model study with genetic and pharmacological manipulation. Female mice. Intervention: Clozapine administration; genetic deletion of Kir7.1 in MC4R neurons; pharmacological inhibition of Kir7.1. Compared with: Vehicle or wild-type control; antipsychotic behavioral assays.
Clozapine promotes obesity in female mice by driving hyperphagia via MC4R-Kir7.1 functional coupling Genetic deletion of Kir7.1 in MC4R neurons reverses clozapine-induced weight gain Pharmacological inhibition of Kir7.1 reverses clozapine-induced weight gain while preserving antipsychotic behavioral efficacy
Pharmacological inhibition of Kir7.1 reverses clozapine-induced weight gain while preserving antipsychotic behavioral efficacy
This identifies a putative mechanism and druggable target (Kir7.1) for mitigating antipsychotic-induced weight gain in preclinical studies. Clinical validation, safety profiling, and testing in humans will be required before any therapeutic application.
Mechanistic study in a mouse model proposing a novel signaling pathway for clozapine-induced weight gain, without evidence of clinical translation or validation in humans.
As stated by the source record.
This identifies a putative mechanism and druggable target (Kir7.1) for mitigating antipsychotic-induced weight gain in preclinical studies. Clinical validation, safety profiling, and testing in humans will be required before any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Most antipsychotic drugs (APDs) cause hyperphagia and weight gain, yet the neural mechanisms underlying these metabolic side effects remain elusive, in part due to difficulties in modeling them in rodents. Here, we establish a mouse model that recapitulates clozapine-induced metabolic syndrome, enabling mechanistic investigation of this widely prescribed APD. We show that clozapine promotes obesity in female mice by driving hyperphagia, which requires functional coupling between the melanocortin 4 receptor (MC4R) and the Kir7.1 potassium channel. Within the broader context of clozapine's polypharmacology, this signaling axis emerges as a critical downstream convergence node for APD-induced metabolic dysfunction. Mechanistically, clozapine inhibits MC4R-expressing neurons in the paraventricular nucleus of the hypothalamus by enhancing MC4R-Kir7.1 coupling, thereby increasing inward potassium currents. Notably, clozapine produces this inhibition without binding the MC4R orthosteric site and without engaging canonical Gαs signaling. Genetic deletion of Kir7.1 in MC4R neurons or pharmacological inhibition of Kir7.1 reverses clozapine-induced weight gain while preserving its behavioral efficacy in established antipsychotic assays. Together, these findings reveal a G-protein-independent mechanism by which clozapine disrupts energy balance and identify MC4R-Kir7.1 coupling as a therapeutically tractable pathway for mitigating APD-associated metabolic dysfunction.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.